Summary:
This study was conducted to determine if the accelerated telomere attrition that occurs as a consequence of allogeneic stem cell transplantation leads to measurable functional defects. Telomere lengths in mononuclear leukocytes obtained from 15 long-term allogeneic stem cell transplant recipients and their respective donors were determined by Southern hybridization and densitometric analysis. Functional assays evaluated the ability of these cells to proliferate in response to a mitogenic stimulus and to differentiate under appropriate cytokine stimulation. Lymphocyte proliferation in response to phytohemagglutinin was determined by measurement of 3 [H]thymidine uptake. The ability of circulating myeloid cells to differentiate was determined after incubation of peripheral blood mononuclear cells with IL-3 and GM-CSF. A total of 13 patients demonstrated telomeric loss, ranging from 0.1 to 3.7 kbp. Strikingly, lymphocytes from 14 of the 15 patients demonstrated a significant decrease in proliferation when compared to their respective donors (68%722, P ¼ 0.001). All patients demonstrated at least a 50% decrease in the number of myeloid colony-forming units when compared to their respective donors (Po0.0001). A decreased ability of hematopoietic cells to proliferate and differentiate is phenotypically consistent with an aged immune system. This may correlate with diminished clinically relevant immune responses to infection or vaccination, as seen in the elderly. and sequence-specific DNA binding proteins. [1] [2] [3] [4] Telomeres confer stability on naturally occurring chromosome ends and render them resistant to nucleolytic attack and chromosome rearrangements. With each somatic cell division, telomere length will shorten as complete replication of chromosomal termini is hampered by the unidirectional nature and primer requirements of conventional DNA polymerases. RNA-primed DNA synthesis of the lagging strand results in a terminal gap after degradation of the most distal primer. In addition to this, the single-stranded GT-rich 3 0 overhang at each telomere involves the action of a putative 5 0 -3 0 exonuclease that degrades the 5 0 end of the underhanging CA-rich strand. 5 Both of these processes lead to shortening of the telomeric DNA template that is available for semiconservative replication in the next round of DNA synthesis. In most normal somatic cells, therefore, telomeres shorten with every cell division. 6 In normal germline cells and over 80% of human cancer cells, telomeric lengths are maintained by a specialized reverse transcriptase, telomerase, that uses an RNA moiety as a template for the addition of telomeric sequences onto the 3 0 end of an existing DNA molecule. 7 The loss of telomeric repeats in somatic cells limits the total number of divisions a cell may undergo. 8, 9 Recently, it has been demonstrated that forced expression of telomerase prevents both telomere erosion and senescence in telomerase-negative cell types. [10] [11] [12] Thus, telomere length is thought to contribute to aging by limiting the self-renewal potential of a variety of tissues, including hematopoietic cells. [13] [14] [15] The first indication that telomere length may limit cell division in the hematopoietic system came from the observation that telomere erosion occurs with age in nucleated hematopoietic cells. 10, 16 Telomeres are shorter in adult bone marrow, with an average length of 10 kb, than in cord blood, with an average length of 15 kb. 8, 17 Likewise, telomere length in peripheral blood lymphocytes decreases with increasing age throughout life, at a rate of approximately 30-56 bp/year. 8, 18, 19 This loss occurs despite telomerase expression in hematopoietic stem cells and telomerase induction in actively dividing T and B lymphocytes. 20 When human T cells are stimulated to proliferate in vitro, high levels of telomerase are initially induced, with no significant telomere loss. However, upon repeated stimulation, the degree of telomerase induction decreases progressively and telomeres shorten. 21 Telomeres are shorter in the lymphocytes of patients who have been treated with chemotherapy, than in normal, agematched controls. 22, 23 These prematurely shortened telomeres may be a result of the extra cell divisions this tissue must undergo to overcome the toxic effects of chemotherapy. This hypothesis is supported by studies that have documented accelerated telomere shortening in patients who have undergone high-dose chemotherapy with allogeneic bone marrow transplant. 18, 24 Telomere length was significantly reduced in the recipients compared to their respective donors, and the extent of reduction correlated inversely with the number of nucleated cells infused. 19 Furthermore, this accelerated loss is limited to the first year post transplant, with subsequent telomere shortening occurring at a normal rate, supporting the hypothesis that this loss is a result of extra cell division. 19, 25, 26 Despite increased hematopoietic demands early after transplantation, normal peripheral blood counts are maintained in long-term allogeneic recipients, even though their telomere lengths remain shorter than their respective donors. 27 The functional significance of prematurely shortened telomeres has yet to be determined and is controversial. 28 The objective of this study is to determine if telomere loss in patients who have undergone and completely recovered from an allogeneic stem cell transplant results in measurable functional consequences. Here we confirm that telomeres are significantly shorter in long-term survivors of allogeneic stem cell transplantation compared with their donors. This is associated with hematopoietic functional impairment as evidenced by a decreased ability of lymphocytes to proliferate in response to mitogenic stimulation and for progenitor cells to undergo myeloid differentiation.
Patients and methods

Patient samples
The Fox Chase-Temple Bone Marrow Transplant patient database was screened for potential patient/donor pairs. Eligible patients were at least 1 year out from allogeneic stem cell transplant, demonstrated complete engraftment by short tandem repeat analysis, and no longer required immunosuppressive therapy. Patients had no clinical evidence of recurrent disease. The protocol was approved by the Fox Chase Cancer Center and Temple University Institutional Review Boards. All patients and donors provided written consent. Whole-blood samples were obtained from the stem cell recipients and their respective donors and buccal swabs were obtained from the recipients for engraftment studies. Mononuclear leukocytes were isolated from peripheral blood by centrifugation using a Ficoll-Paque density gradient. Peripheral blood mononuclear cells were divided and used for subsequent assays as described below.
Engraftment studies
Engraftment studies were carried out at the University of Pennsylvania Department of Laboratory and Pathology Medicine under a contractual agreement. DNA was extracted from the post transplant specimen and evaluated at a previously identified informative short tandem repeat (STR) locus by polymerase chain reaction (PCR) using a GenePrintt Fluorescent STR quadriplex assay (Promega, Inc.). 29 PCR products were electrophoresed using an ABI 310 GeneScan Analyzer followed by analysis with GEN-ESCAN and Genotyper software for allele identification, size determination and quantitation. The peak area of the scanned PCR product bands was used for relative quantification of donor and recipient DNAs in the post transplant specimen by dividing the recipient-specific allele peak areas by the sum of the recipient-and donor-specific allele areas. 30 
Determination of telomere length
Genomic DNA was isolated from at least 1 Â 10 7 cells using sodium dodecyl sulfate (SDS) lysis, phenol/chloroform extraction, and isopropanol precipitation. Samples were stored at À201C. Telomere length was determined by Southern analysis. Terminal restriction fragments composed of the telomeric repeat array and associated subtelomeric sequences were generated by DNA digestion with Hinfl and Rsal. Digested DNA was size fractionated on 0.7% agarose gels and the DNA transferred to a Hybond N filter (Amersham) by capillary transfer. The terminal restriction fragments were visualized following hybridization with a mixture of two oligonucleotide probes complimentary to the telomeric repeats, 5 0 (TTAGGG) 4 3 0 and 5 0 (CCCTAA)3 0 . A measure of 100 ng of each oligonucleotide was labeled at its 5 0 end using T4 polynucleotide kinase and [g-32 P]ATP. 31 Telomere length was determined by densitometric analysis using software developed at Fox Chase Cancer Center (http://bioinformatics.fccc.edu/ software). 32 Total telomere loss was determined by calculating the difference in the modal telomere length between each patient and his/her respective donor.
Lymphocyte proliferation assay
The ability of T cells isolated from patients and donors to proliferate in response to mitogenic or antigenic stimulation was determined and compared. Immediately after isolation, peripheral blood mononuclear cells (PBMCs) were cultured in triplicate at a concentration of 1 Â 10 5 cells per well in RPMI-1640 (Gibco, BRL) supplemented with HEPES, NaHCO 3 , glutamine, penicillin, and streptomycin. Lymphocyte proliferation was assayed in medium alone and medium plus 5 mg/ml phytohemagglutinin (PHA-L; Boehringer-Mannheim), a nonspecific stimulator of CD3 þ cells. Cells were cultured for a period of 5 days. At 16-18 h prior to harvest, 1 mCi [H]thymidine was added per well. Cells were harvested using a semiautomated cell harvester and the incorporated radioactivity was measured by scintillation spectroscopy. Results are expressed as c.p.m.7s.e.m. of the triplicates.
Colony-forming assays
In order to determine and compare the ability of circulating progenitor cells from patient and donor to form myeloid colonies, 2 Â 10 6 PBMCs were plated in a semisolid culture medium (McCoys 5A supplemented with fetal calf serum, sodium pyruvate, L-serine, L-asparagine, sodium bicarbonate and Eagles MEM vitamins, essential and nonessential amino acids; Gibco) with IL-3 (50 U; R&D Systems) and rhGM-CSF (50 U/cm 3 ; R&D Systems). Duplicate cultures were incubated for 14 days in a humidified 371C, 5% CO 2 incubator, and colonies scored using an inverted microscope as per standard protocols. 33 
Statistical methods
Descriptive and exploratory analyses were conducted for all variables to characterize the sample and describe the population for which subsequent inferences were made. Their distributional properties were examined to determine if variance stabilizing or normalizing transformations should be applied. Pearson's correlation coefficient was used to quantify the linear dependency between pairs of variables. Paired t-test was used to make inferences for responses that were related in a pairwise manner. The critical level of significance was set to 5%. Analyses were performed using Minitabt.
Results
Based on the observations that telomeres shorten with age and that recipients of allogeneic stem cell transplantation have shorter telomeres than their respective donors, we hypothesized that there would be measurable functional consequences as a result of this loss. This study was undertaken to determine if telomere length or loss influenced the ability of hematopoietic cells to proliferate and/or differentiate by comparing measurable functional differences and telomere length between recipients and their donors.
Baseline characteristics
A total of 15 patient/donor pairs who met the eligibility criteria were enrolled. Patients were at least 1 year out from allogeneic stem cell transplantation, ranging from 1.5 to 10.5 years, with a median of 5.5 years from transplant. All patients underwent allogeneic transplantation for a hematologic disorder. Five patients each were transplanted for acute myelogenous leukemia (AML) or chronic myelogenous leukemia (CML). Two patients were treated for aplastic anemia (AA) and one patient each was diagnosed with acute lymphocytic leukemia (ALL), multiple myeloma (MM), and myelodysplastic syndrome (MDS) ( Table 1 ). The stem cell recipients' age ranged from 27 to 60 years with a median age of 48 years. The donors ranged in age from 26 to 69 years with a median age of 46 years. Of the 15 patients, 14 received stem cells from an HLA-matched sibling. Half of the recipients were younger than their sibling donors (range 2-9 years, average 4.7 years) and half of the recipients were older than their sibling donors (range 2-10, average 5 years). The greatest difference in age between recipient and donor was seen in the only fatherson pair (32 years). Of the 15 patient/donor pairs, eight were same sex matches. All patients demonstrated 100% donor engraftment by short tandem repeat analysis and had no longer required immunosuppressive therapy for graft-versus-host disease for at least 6 months prior to the sample collection. Of the 15 patients, 12 had a recent CBC documented around the time of the study sample. All 12 patients had a normal WBC and normal absolute neutrophil count.
Telomere loss
In order to determine the extent of telomere loss in the PBMCs of recipients compared with their respective donors, DNA was isolated from the buffy coat layer of whole-blood specimens, and telomeric DNA length was measured using Southern hybridization and densitometric methods ( Figure 1a) . As has been reported previously, the majority of recipients demonstrated shorter telomeres than their donors. Of the 15 patients, 13 demonstrated significant telomere loss compared with their respective Interestingly, these were noted in patient/donor pairs with relatively short donor telomere lengths (6.5 kb), and were the two oldest donors in the study. Only one other donor in the study had a shorter length of 6.3 kb (donor # 2). Although the greatest extent of loss was associated with longer starting telomeres, and the least amount of loss was noted in donors with relatively shorter telomeres, this trend did not reach statistical significance in this limited sample size. As expected, the extent of telomere loss did not correlate with time from transplantation. Given the wide intersubject variability, telomere length did not directly correlate with donor age. When the telomere length of post transplant recipients and donors is plotted against donor age, the slope of the linear regression line is much steeper for the donors than the recipients (Figure 1c) . While the donors have longer telomeres than the recipients for any given age, the linear regression lines are not parallel and begin to converge with increasing age. This suggests that there may be a critically short telomere length at which time the cells are removed from the circulating population.
Lymphocyte proliferation assay
In order to determine if telomere length or loss, as measured in the whole population of PBMCs, influenced the ability of lymphocytes to divide in response to mitogenic stimulation, tritiated thymidine uptake as a reflection of lymphocyte proliferation was measured in both recipients and donors. The background level of radioactivity in the wells with media alone or with cells in the absence of PHA-L was negligible compared to the wells stimulated with PHA-L. Of the 15 patients, 14 demonstrated a decreased ability to proliferate in response to mitogenic stimulation with PHA-L compared with their respective donors. On an average, tritiated thymidine uptake in recipients was 67% that of the donors, ranging from 24 to 106% (P ¼ 0.001) (Figure 2 ). There were no consistent correlations between the extent of thymidine uptake and telomere length of the donor or recipient PBMCs (P ¼ 0.73), nor was there a significant correlation between the extent of telomere loss and the differences between thymidine uptake (P ¼ 0.83). However, those pairs with the least amount of telomere loss tended to have the smallest differences in thymidine uptake (pairs # 6, 8, and 12) and those pairs with the greatest amount of telomere loss had the biggest differences in uptake (pairs # 4, 5, and 11).
Myeloid colony-forming units (CFUs)
In order to determine if telomere length or loss in the PBMCs of recipients resulted in a compromised ability of circulating myeloid progenitor cells to differentiate under appropriate cytokine stimulation with IL-3 and GM-CSF, colony-forming assays were performed. All 15 recipients demonstrated a decreased ability to form granulocytemacrophage colony-forming units (CFU-GM) compared with their respective donors. On an average, recipients formed 66% fewer colonies, ranging from 50 to 85% inhibition compared with their respective donors (Po0.0001) (Figure 3 ). In addition to fewer colonies, morphologically the recipients' colonies were consistently smaller, with fewer cells per colony (data not shown). Again, there was no correlation between the number of CFUs and telomere length in the donors. There was a trend toward a correlation between CFUs of the recipient and recipient telomere length (P ¼ 0.061) in this small number of samples. Similar to the lymphocyte proliferation assay, those pairs with the least amount of telomere loss tended to have the smallest differences in the number of myeloid CFUs (pairs # 6 and 12) and those pairs with the greatest degree of loss had the largest differences in the number of colonies formed (pairs # 5, 10, 11, and 14). The extent of telomere loss, however, did not reliably predict for the degree of difference between the number of CFUs in the recipient and donor.
Discussion
Telomeres serve to protect genomic integrity by preventing nucleolytic attack and end-to-end chromosome fusions. Critically, short telomeres result in massive genomic instability 34 and may be linked to age-related clonal disorders such as myelodysplastic syndromes, 35 or secondary malignancies seen in patients who have been previously treated with immunosuppressive chemotherapeutic regimens. [36] [37] [38] [39] Since telomeric sequences are lost with each somatic cell division, telomere length reflects the number of divisions a cell has undergone and may predict the remaining replicative potential of a cell population. 8, 40, 41 However, the relevance of telomere-dependent replicative senescence to immune dysfunction in the elderly remains controversial. 28 Many lines of evidence do not support the theory that telomere length plays a crucial role in immunosenescence. For example, age-dependent immune decline in mice occurs rapidly despite relatively long telomeres. Similarly, despite relatively longer telomeres in naive T cells, proliferation of this subset declines with age. While average telomere length gradually decreases with age, there is marked individual variability, suggesting genetically regulated heterogeneities between individuals. There may be intersubject differences in the critical telomere length set points that trigger apoptosis or genomic instability. Furthermore, it has been shown that the shortest telomere in a given cell rather than the average or most frequent telomere length dictates its cellular response. 42 In this study, we confirmed that there is a significant loss of telomeric DNA in recipients of allogeneic transplantation compared with their respective donors. Furthermore, we identified measurable functional differences in both lymphoid and myeloid lineages between recipients and their respective donors. In this patient population, recipients lost an average of 890 bp as a result of transplantation, which is comparable to previously published results. 24, 25, 27, 43, 44 Many investigators have noted less shortening with higher numbers of nucleated cells infused at the time of transplant 25 or in patients who receive G-CSF-mobilized peripheral blood stem cells rather than bone marrow, 45 while others report telomere loss regardless of the numbers of infused cells. 44 Several studies have shown that this accelerated telomere loss occurs within the first year post transplant with subsequent telomere loss continuing at a normal rate. 19, 25, 26 Most recently, it has been suggested that telomere homeostasis, rather than shortening, may occur during the first year after transplantation in patients who receive G-CSF-mobilized peripheral blood stem cells rather than bone marrow, 45 although this was not supported in the few patients in our study who received PBSCs. Given these findings, accelerated loss is most likely a result of the rapid cell division the hematopoietic system must undergo in the first year in order to reconstitute the bone marrow compartment after marrow ablation, and this loss may be attenuated by increasing the numbers of hematopoietic cells infused.
It has been recognized that, despite normal peripheral blood cell counts and normocellular marrows as early as 2 months post transplant, both autologous and allogeneic stem cell transplantations result in prolonged impairment of clonogenic precursors. [46] [47] [48] [49] While the precursor frequencies increased over time in recipients post transplant, they rarely ever returned to normal levels, continuing to remain 20-40% of that of the donor population even 3 years later. 49 In patients undergoing autologous stem cell transplant, CFU-GMs and erythroid burst-forming units (BFU-E) may take up to 2 years to reach pre-graft levels, erythroid CFUs (CFU-E) up to 4 years to recover, and megakaryocyte CFUs (CFU-Meg) even longer. 48 These findings should be taken into account when comparing the telomere lengths in different hematopoietic subsets at different timepoints from transplant. The results of our study suggest that CFU-GMs in most allogeneic recipients never return to that of their donors even up to 10 years post transplant.
Several hypotheses have been offered to explain the longterm clonogenic dysfunction noted after allogeneic transplant. While critical shortening of telomeres as a result of cell division may play a role, additional factors contributing to delayed or impaired clonogenic recovery include alloimmunity, immunosuppressive regimens, and acute or chronic GVHD, which may predispose recipients to immunosuppressive infections such as cytomegalovirus. Conditioning regimens that include total body irradiation (TBI), cyclophosphamide, and busulfan may induce longterm damage to the bone marrow stromal cells, which may in turn decrease the endogenous production of hematopoietic growth factors. 50 In addition, insults to the stem cell product as a result of cryopreservation, damage to the microenvironment as a result of prior chemotherapeutic treatments and a requirement for significant population doubling to repopulate the marrow compartment are inevitable.
In our study, we evaluated functional parameters of lymphocyte proliferation as well as the ability of circulating myeloid precursors to differentiate in response to cytokine stimulation. We noted at least a 50% reduction in the number of CFU-GMs in all 15 patients compared with their respective donors, even in patients 8-10 years out from transplantation, and many years after the discontinuation of immunosuppressive therapy. Of the 15 patients, 14 also demonstrated a significantly decreased ability to proliferate compared with their donors. To our knowledge, this is the first report of measurable differences in lymphocyte proliferation in long-term survivors of allogeneic bone marrow transplantation. While the measurement of telomere length or degree of loss did not accurately predict for the individuals' performance in the functional assays, there were trends suggesting that telomere length may indeed be contributing to this measurable immune dysfunction. This study may have been limited in the ability to detect any correlation between telomere length or attrition and functional loss, as telomere length was measured in the entire population of peripheral blood mononuclear cells and not in the subset of the population tested in each functional assay. This may partially explain why the correlative trend between CFU-GM and telomere length did not reach statistical significance. In addition, while the number of lymphocytes in the peripheral blood of transplant recipients might be within the normal range, the percentage of CD4 þ T cells in the PBMC fraction may be relatively low even at 5 years post transplant; thus, a low proliferation score may not simply reflect a decreased proliferative capacity. Lastly, the telomere length reported reflects the most frequent length in the population of cells. There are studies to suggest that the shortest telomere in a given cell dictates that cell's proliferative potential. 42 Immunosenescence has widespread consequences for the development and potential treatment of malignancies. Bone marrow transplantation provides a clinical model for studying the effects of proliferation, cell damage, and immune function. Although telomere loss may contribute to immune dysfunction in the recipients of allogeneic stem cell transplant, our studies suggest that this is not the critical factor. Additional studies are needed to identify potential long-term consequences of this treatment, the underlying biological mechanisms contributing to unfavorable phenotypes and methods to circumvent this potentially harmful complication of therapy.
